Sivelestat sodium is a competitive inhibitor of human neutrophil elastase (IC50 = 44 nM; Ki = 200 nM) with potential applications in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC) associated with COVID-19. It has demonstrated efficacy in suppressing human neutrophil elastase-induced lung hemorrhage in hamsters and increased skin capillary permeability in guinea pigs. In rat models, sivelestat ameliorates lung injury following hemorrhagic shock and prevents ischemia–reperfusion injury in the bladder.